

June 25, 2014

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (bc-52)

GILTERITINIB FUMARATE

PRONUNCIATION

gil" te ri' ti nib


THERAPEUTIC CLAIM

Treatment of acute myeloid leukemia

CHEMICAL NAMES

1. 2-Pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2*H*-pyran-4-yl)amino]-, (2*E*)-2-butenedioate (2:1)
2. 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-(oxan-4-ylamino)pyrazine-2-carboxamide hemi-(2*E*)-but-2-enedioate

STRUCTURAL FORMULA



MOLECULAR FORMULA

 $(C_{29}H_{44}N_8O_3)_2 \cdot C_4H_4O_4$

MOLECULAR WEIGHT

1221.5

TRADEMARK

None as yet

SPONSOR

Astellas Pharma Global Development Inc.

CODE DESIGNATIONS

ASP2215 hemifumarate

CAS REGISTRY NUMBER

1254053-84-3

UNII

5RZZ0Z1GJT

gbk